1153

    500660

    GLAXO

    img img img img
    No Data Available

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    GLAXOSMITHKLINE PHARMA LT Share Price Today

    GLAXOSMITHKLINE PHARMA LT is currently trading at ₹2614.7, up by ₹63.5 from the previous close. The stock touched an intraday high of ₹2617.90 and a low of ₹2538.80 during the latest trading session. Over the past one year, GLAXOSMITHKLINE PHARMA LT has delivered a loss of 17.26%, while the stock has gained 8.35% in the last one month.

    GLAXOSMITHKLINE PHARMA LT performance

    Today’s low Today’s high
    ₹ 2538.80 ₹ 2617.90
    ₹ 2612.00
    52 week low 52 week high
    ₹ 2088.10 ₹ 3200.00
    ₹ 2612.00
    Open Price ₹ 2553.90
    Prev. Close ₹ 2551.20
    Volume (Shares) 49764.00
    Total traded value ₹ 1299.83
    Upper Circuit ₹ 3061.40
    Lower Circuit ₹ 2041.00
    info

    Investment Returns

    Over 1 Month 8.35% Over 3 Months 4.59% Over 6 Months 8.98% Over 1 Year -17.26%
    demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

    GLAXOSMITHKLINE PHARMA LT fundamentals


    • Market cap (Cr) 44,248.90
    • P/E Ratio (TTM) 42.70
    • Beta 0.55
    • Book Value / share 132.29
    • Return on equity 48.29%
    • EPS (TTM) 53.59
    • Dividend yield 2.24%
    • Net profit/quarter (Cr) 274.94
    info icon alternate text
    • Market cap (Cr) 44,299.70
    • P/E Ratio (TTM) 42.70
    • Beta 0.51
    • Book Value / share 132.29
    • Return on equity 48.29%
    • EPS (TTM) 53.59
    • Dividend yield 2.24%
    • Net profit/quarter (Cr) 274.94
    info icon alternate text

    GLAXOSMITHKLINE PHARMA LT Financials

    • Key Results
    • Key Ratios
    • Balance sheet
    • Cash Flow
    • Competition
    Open financial information
    Revenue
    Net income
    Particulars MAR 2026 (Values in Cr)
    Revenue 989.15
    Operating Expense 655.74
    Net Profit 274.94
    Net Profit Margin (%) 27.79
    Earnings Per Share (EPS) 16.23
    EBITDA 382.90
    Effective Tax Rate (%) 25.51
    Particulars DEC 2025 (Values in Cr)
    Revenue 1022.59
    Operating Expense 676.52
    Net Profit 277.18
    Net Profit Margin (%) 27.10
    Earnings Per Share (EPS) 16.36
    EBITDA 399.40
    Effective Tax Rate (%) 26.65
    Particulars SEP 2025 (Values in Cr)
    Revenue 973.63
    Operating Expense 656.89
    Net Profit 255.00
    Net Profit Margin (%) 26.19
    Earnings Per Share (EPS) 14.92
    EBITDA 368.59
    Effective Tax Rate (%) 27.27
    Particulars JUN 2025 (Values in Cr)
    Revenue 804.83
    Operating Expense 570.02
    Net Profit 204.70
    Net Profit Margin (%) 25.43
    Earnings Per Share (EPS) 12.08
    EBITDA 294.51
    Effective Tax Rate (%) 26.51
    Particulars MAR 2025 (Values in Cr)
    Revenue 966.08
    Operating Expense 650.64
    Net Profit 260.14
    Net Profit Margin (%) 26.92
    Earnings Per Share (EPS) 15.35
    EBITDA 370.20
    Effective Tax Rate (%) 26.70
    Particulars MAR 2026 (Values in Cr)
    Revenue 3790.20
    Operating Expense 2559.17
    Net Profit 1011.82
    Net Profit Margin (%) 26.69
    Earnings Per Share (EPS) 59.59
    EBITDA 1445.40
    Effective Tax Rate (%) 26.47
    Particulars MAR 2025 (Values in Cr)
    Revenue 3723.49
    Operating Expense 2622.29
    Net Profit 919.06
    Net Profit Margin (%) 24.68
    Earnings Per Share (EPS) 54.01
    EBITDA 1316.54
    Effective Tax Rate (%) 26.38
    Particulars MAR 2024 (Values in Cr)
    Revenue 3407.25
    Operating Expense 2578.08
    Net Profit 584.69
    Net Profit Margin (%) 17.16
    Earnings Per Share (EPS) 40.83
    EBITDA 880.52
    Effective Tax Rate (%) 27.73
    Particulars MAR 2023 (Values in Cr)
    Revenue 3216.34
    Operating Expense 2484.50
    Net Profit 607.75
    Net Profit Margin (%) 18.89
    Earnings Per Share (EPS) 35.88
    EBITDA 899.95
    Effective Tax Rate (%) 27.35
    Particulars MAR 2022 (Values in Cr)
    Revenue 3217.51
    Operating Expense 2531.85
    Net Profit 1690.53
    Net Profit Margin (%) 52.54
    Earnings Per Share (EPS) 99.79
    EBITDA 843.63
    Effective Tax Rate (%) 51.31
    Particulars MAR 2026 (Values in Cr)
    Book Value / Share 133.85
    ROE % 49.11
    ROCE % 59.05
    Total Debt to Total Equity 0.01
    EBITDA Margin 38.60
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 115.19
    ROE % 49.75
    ROCE % 59.29
    Total Debt to Total Equity 0.01
    EBITDA Margin 35.42
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 104.93
    ROE % 37.32
    ROCE % 44.97
    Total Debt to Total Equity 0.01
    EBITDA Margin 28.42
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 102.79
    ROE % 27.73
    ROCE % 33.92
    Total Debt to Total Equity 0.01
    EBITDA Margin 27.89
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 157.19
    ROE % 81.31
    ROCE % 32.55
    Total Debt to Total Equity 0.01
    EBITDA Margin 25.53
    Particulars MAR 2026 (Values in Cr)
    Book Value / Share 132.30
    ROE % 48.29
    ROCE % 58.17
    Total Debt to Total Equity 0.01
    EBITDA Margin 38.14
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 115.06
    ROE % 49.23
    ROCE % 58.72
    Total Debt to Total Equity 0.01
    EBITDA Margin 35.36
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 105.31
    ROE % 36.83
    ROCE % 44.44
    Total Debt to Total Equity 0.01
    EBITDA Margin 28.60
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 103.48
    ROE % 27.43
    ROCE % 33.60
    Total Debt to Total Equity 0.01
    EBITDA Margin 28.08
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 158.06
    ROE % 80.45
    ROCE % 32.11
    Total Debt to Total Equity 0.01
    EBITDA Margin 25.83
    Particulars MAR 2026 (Values in Cr)
    Cash & Short Term Investments 1391.01
    Total Assets 4323.86
    Total Liabilities 4323.86
    Total Equity 2267.41
    Share Outstanding 16
    Price to Book Ratio 17.26
    Return on Assets (%) 23.95
    Return on Capital (%) 45.69
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 1403.51
    Total Assets 4108.06
    Total Liabilities 4108.06
    Total Equity 1951.31
    Share Outstanding 16
    Price to Book Ratio 25.01
    Return on Assets (%) 22.57
    Return on Capital (%) 47.54
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 1063.21
    Total Assets 3556.61
    Total Liabilities 3556.61
    Total Equity 1777.63
    Share Outstanding 16
    Price to Book Ratio 18.45
    Return on Assets (%) 16.58
    Return on Capital (%) 33.19
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 1155.92
    Total Assets 3326.58
    Total Liabilities 3326.58
    Total Equity 1741.27
    Share Outstanding 16
    Price to Book Ratio 12.80
    Return on Assets (%) 18.35
    Return on Capital (%) 35.07
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 2484.50
    Total Assets 4633.27
    Total Liabilities 4633.27
    Total Equity 2662.95
    Share Outstanding 16
    Price to Book Ratio 10.52
    Return on Assets (%) 36.57
    Return on Capital (%) 63.64
    Particulars MAR 2026 (Values in Cr)
    Cash & Short Term Investments 1354.79
    Total Assets 4274.91
    Total Liabilities 4274.91
    Total Equity 2241.17
    Share Outstanding 16
    Price to Book Ratio 17.26
    Return on Assets (%) 23.66
    Return on Capital (%) 45.15
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 1400.88
    Total Assets 4100.93
    Total Liabilities 4100.93
    Total Equity 1949.23
    Share Outstanding 16
    Price to Book Ratio 25.01
    Return on Assets (%) 22.41
    Return on Capital (%) 47.15
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 1061.19
    Total Assets 3547.80
    Total Liabilities 3547.80
    Total Equity 1784.09
    Share Outstanding 16
    Price to Book Ratio 18.45
    Return on Assets (%) 16.48
    Return on Capital (%) 32.77
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 1150.73
    Total Assets 3327.69
    Total Liabilities 3327.69
    Total Equity 1752.99
    Share Outstanding 16
    Price to Book Ratio 12.80
    Return on Assets (%) 18.26
    Return on Capital (%) 34.67
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 2479.11
    Total Assets 4622.59
    Total Liabilities 4622.59
    Total Equity 2677.61
    Share Outstanding 16
    Price to Book Ratio 10.52
    Return on Assets (%) 36.57
    Return on Capital (%) 63.14
    Particulars MAR 2026 (Values in Cr)
    Net Income 1385.38
    Cash from Operations 1221.97
    Cash from Investing 396.98
    Cash from Financing -737.07
    Net change in Cash 563.20
    Free Cash Flow 1277.25
    Particulars MAR 2025 (Values in Cr)
    Net Income 1255.18
    Cash from Operations 1371.60
    Cash from Investing -45.80
    Cash from Financing -769.42
    Net change in Cash 474.67
    Free Cash Flow 1394.62
    Particulars MAR 2024 (Values in Cr)
    Net Income 959.80
    Cash from Operations 975.69
    Cash from Investing 8.71
    Cash from Financing -561.49
    Net change in Cash 29.23
    Free Cash Flow 1006.91
    Particulars MAR 2023 (Values in Cr)
    Net Income 841.49
    Cash from Operations 755.74
    Cash from Investing 807.85
    Cash from Financing -1543.32
    Net change in Cash -251.24
    Free Cash Flow 799.78
    Particulars MAR 2022 (Values in Cr)
    Net Income 2475.64
    Cash from Operations 959.03
    Cash from Investing -405.50
    Cash from Financing -524.24
    Net change in Cash -119.00
    Free Cash Flow 993.67
    Particulars MAR 2026 (Values in Cr)
    Net Income 1373.58
    Cash from Operations 1201.52
    Cash from Investing 385.25
    Cash from Financing -737.07
    Net change in Cash 529.60
    Free Cash Flow 1256.80
    Particulars MAR 2025 (Values in Cr)
    Net Income 1243.74
    Cash from Operations 1360.95
    Cash from Investing -36.53
    Cash from Financing -769.42
    Net change in Cash 474.07
    Free Cash Flow 1383.97
    Particulars MAR 2024 (Values in Cr)
    Net Income 952.65
    Cash from Operations 971.05
    Cash from Investing 14.96
    Cash from Financing -561.49
    Net change in Cash 32.40
    Free Cash Flow 1002.27
    Particulars MAR 2023 (Values in Cr)
    Net Income 837.48
    Cash from Operations 757.61
    Cash from Investing 805.19
    Cash from Financing -1544.17
    Net change in Cash -251.04
    Free Cash Flow 801.65
    Particulars MAR 2022 (Values in Cr)
    Net Income 2470.04
    Cash from Operations 968.00
    Cash from Investing -419.66
    Cash from Financing -524.24
    Net change in Cash -124.11
    Free Cash Flow 1002.64
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 31.80 13.20 1.53 243.69 23.12 38.85
    BLISS GVS PHARMA LTD 461.00 37.06 4.09 4889.19 118.35 552.90
    CIPLA LTD. 1409.85 31.83 3.30 113894.07 1165.55 1672.20
    FERMENTA BIOTECH LTD. 444.00 20.77 3.21 1306.74 256.40 480.00
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 31.80 22.24 4.09 243.69 23.12 38.85
    AMRUTANJAN HEALTH CARE LTD. 513.60 23.02 4.01 1484.85 490.00 789.95
    ASTRAZENECA PHARMA INDIA LTD. 8167.90 106.74 23.39 20419.75 7630.00 9850.00
    BLISS GVS PHARMA LTD 461.00 49.84 4.23 4889.19 118.35 552.90

    GLAXOSMITHKLINE PHARMA LT shareholding pattern

    Holding
    12.41%
    75.0%
    4.78%
    7.8%
    Name Shares Category
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)

    News

    Left Arrow
    Right Arrow

    GLAXOSMITHKLINE PHARMA LT Technicals Summary

    • EMA & SMA
    • Resistance and Support
    • Delivery and Volume
    • Beta
    • Price Change Analysis
    2612.00 2.38 redarrow
    red-green-graph indicator
    0 Bearish
    16 Bullish
    • 5 Days 2521.10
    • 26 Days 2438.40
    • 10 Days 2499.30
    • 50 Days 2400.60
    • 12 Days 2490.60
    • 100 Days 2408.90
    • 20 Days 2457.70
    • 200 Days 2473.00
    2536.37 PIVOT
    First Support 2508.93 First Resistance 2578.63 Second Support 2466.67 Second Resistance 2606.07 Third Support 2439.23 Third Resistance 2648.33
    RSI 64.83 ADX 56.96 MACD 52.24 Williams % R -10.23 Commodity Channel Index (CCI) 136.65
    Date 2026-07-27 Week 36368.00 Same Day 39025.00 Month 44635.00
    1 Year 0.55 3 Year 0.62
    Over 1 Month
    8.35% down
    Over 1 Year
    -17.26% down
    Over 3 Months
    4.59% down
    Over 3 Years
    22.13% down
    Over 6 Months
    8.98% down
    Over 5 Years
    8.77% down

    GLAXOSMITHKLINE PHARMA LT Corporate Actions

    Dividend date Dividend amount Dividend type Record date Instrument type
    29 May 2026 57.0 Final 29 May 2026 Equity shares
    30 May 2025 42.0 Final 30 May 2025 Equity shares
    07 Nov 2024 12.0 Special 07 Nov 2024 Equity shares
    31 May 2024 32.0 Final 31 May 2024 Equity shares
    30 Jun 2023 32.0 Final 30 Jun 2023 Equity shares
    07 Jul 2022 60.0 Special 08 Jul 2022 Equity shares
    07 Jul 2022 30.0 Final 08 Jul 2022 Equity shares
    19 Jul 2021 30.0 Final 20 Jul 2021 Equity shares
    17 Jul 2020 20.0 Special 20 Jul 2020 Equity shares
    17 Jul 2020 20.0 Final 20 Jul 2020 Equity shares
    11 Jul 2019 20.0 Final 15 Jul 2019 Equity shares
    13 Jul 2018 35.0 Final 17 Jul 2018 Equity shares
    14 Jul 2017 30.0 Final 18 Jul 2017 Equity shares
    15 Jul 2016 50.0 Final 19 Jul 2016 Equity shares
    23 Jul 2015 62.5 Final 25 Jul 2015 Equity shares
    03 Apr 2014 50.0 Final 07 Apr 2014 Equity shares
    04 Apr 2013 50.0 Final 08 Apr 2013 Equity shares
    29 Mar 2012 45.0 Final 02 Apr 2012 Equity shares
    14 Mar 2011 40.0 Final 16 Mar 2011 Equity shares
    10 Mar 2010 30.0 Final 12 Mar 2010 Equity shares
    18 Mar 2009 18.0 Special 20 Mar 2009 Equity shares
    18 Mar 2009 22.0 Final 20 Mar 2009 Equity shares
    02 Apr 2008 18.0 Special 04 Apr 2008 Equity shares
    02 Apr 2008 18.0 Final 04 Apr 2008 Equity shares
    14 Mar 2007 14.0 Special 16 Mar 2007 Equity shares
    14 Mar 2007 17.0 Final 16 Mar 2007 Equity shares
    Ex-Date Ex-Bonus Ratio
    13 Sep 2018 11 Sep 2018 1:1
    Dividend date Dividend amount Dividend type Record date Instrument type
    29 May 2026 57.0 Final 29 May 2026 Equity shares
    30 May 2025 42.0 Final 30 May 2025 Equity shares
    07 Nov 2024 12.0 Special 07 Nov 2024 Equity shares
    31 May 2024 32.0 Final 31 May 2024 Equity shares
    30 Jun 2023 32.0 Final 30 Jun 2023 Equity shares
    07 Jul 2022 60.0 Special 08 Jul 2022 Equity shares
    07 Jul 2022 30.0 Final 08 Jul 2022 Equity shares
    19 Jul 2021 30.0 Final 20 Jul 2021 Equity shares
    17 Jul 2020 20.0 Special 20 Jul 2020 Equity shares
    17 Jul 2020 20.0 Final 20 Jul 2020 Equity shares
    11 Jul 2019 20.0 Final 15 Jul 2019 Equity shares
    13 Jul 2018 35.0 Final 17 Jul 2018 Equity shares
    14 Jul 2017 30.0 Final 18 Jul 2017 Equity shares
    15 Jul 2016 50.0 Final 19 Jul 2016 Equity shares
    23 Jul 2015 62.5 Final 25 Jul 2015 Equity shares
    03 Apr 2014 50.0 Final 07 Apr 2014 Equity shares
    04 Apr 2013 50.0 Final 08 Apr 2013 Equity shares
    29 Mar 2012 45.0 Final 02 Apr 2012 Equity shares
    14 Mar 2011 40.0 Final 16 Mar 2011 Equity shares
    10 Mar 2010 30.0 Final 12 Mar 2010 Equity shares
    18 Mar 2009 18.0 Special 20 Mar 2009 Equity shares
    18 Mar 2009 22.0 Final 20 Mar 2009 Equity shares
    02 Apr 2008 18.0 Special 04 Apr 2008 Equity shares
    02 Apr 2008 18.0 Final 04 Apr 2008 Equity shares
    14 Mar 2007 14.0 Special 16 Mar 2007 Equity shares
    14 Mar 2007 17.0 Final 16 Mar 2007 Equity shares
    Ex-Date Ex-Bonus Ratio
    13 Sep 2018 11 Sep 2018 1:1

    Top Gainers

    Top Losers

    stock
    Trade stocks with ease

    Sign-in to trade with your demat account, or set up a new demat account for free

    Board Of Directors

    Similar stocks

    Frequently Asked Questions

    What is the Current Share Price of Glaxosmithkline Pharmaceuticals Ltd?

    Answer Field

    Glaxosmithkline Pharmaceuticals Ltd share price is for NSE ₹ 2,614.70 & for BSE ₹ 2,616.85 as on Jul 28 2026 02:42 PM.

    What is the Market Cap of Glaxosmithkline Pharmaceuticals Ltd Share?

    Answer Field

    The market cap of Glaxosmithkline Pharmaceuticals Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Jul 28 2026 02:42 PM.

    What is the 52 Week High and Low of Glaxosmithkline Pharmaceuticals Ltd?

    Answer Field

    The 52 Week High and Low of Glaxosmithkline Pharmaceuticals Ltd for NSE is ₹ 3,200.00 and ₹ 2,088.10 and for BSE is ₹ 3,202.80 and ₹ 2,088.00.

    What is 1 year return for Glaxosmithkline Pharmaceuticals Ltd?

    Answer Field

    The 1 year returns on the stock has been -17.26%.

    What is the P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd Share?

    Answer Field

    As on Jul 28 2026 02:42 PM the price-to-earnings (PE) ratio for Glaxosmithkline Pharmaceuticals Ltd share is 42.70.

    What is the PB ratio of Glaxosmithkline Pharmaceuticals Ltd Share?

    Answer Field

    As on Jul 28 2026 02:42 PM, the price-to-book (PB) ratio for Glaxosmithkline Pharmaceuticals Ltd share is 132.29.

    How to Buy Glaxosmithkline Pharmaceuticals Ltd Share?

    Answer Field

    You can trade in Glaxosmithkline Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

    How to Buy Glaxosmithkline Pharmaceuticals Ltd Share on Bajaj Broking App?

    Answer Field

    To buy Glaxosmithkline Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

    • Login to the Bajaj Broking App

    • Click on the Search Icon

    • Search “Glaxosmithkline Pharmaceuticals Ltd”

    • Click on the BUY icon

    • Place a buy order specifying the desired quantity of shares.

    • Click BUY again to complete the purchase

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59
    banner-icon

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |